// App-Quantinova.ai

5005 : PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer.

Researchers

Presenter

  • Hannes Cash

Principal Investigators

  • Ursula Steiner

  • Axel Heidenreich

  • Theodor Klotz

  • Sebastian Melchior

  • Peter Albers

  • Peter Martus

  • Stefan Hinz

  • Ahmed Magheli

  • Carsten Kempkensteffen

  • Kurt Miller

Medical Centers

  • Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany, Berlin, Germany

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Cologne University, Cologne, Germany

  • Klinikum Weiden, Weiden, Germany

  • Dept. of Urology, Bremen, Germany

  • Department of Urology, Heinrich-Heine-University, Duesseldorf, Germany

  • Institute for Clinical Epidemiology and Applied Biometrics, University Hospital Tubingen, Tubingen, Germany

  • Charite University Medicine, Clinic for Urology, Department for Internal Medicine, Berlin, Germany

  • Department of Radiology, Charite University Medical Center, Berlin, Germany

  • Department of Urology, Charite Berlin, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved